Molecular Partners Ag (MOLN) Total Liabilities (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Total Liabilities of $24526.2 for Q1 2026, down 100.0% year-over-year from $14.4 billion in Q1 2025, and up 89935.72% quarter-over-quarter from $27.24 in Q4 2025.
Molecular Partners Ag (MOLN) Total Liabilities (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Total Liabilities for 7 consecutive years, with $24526.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 100.0% year-over-year to $24526.2; the TTM figure through Mar 2026 stood at $24526.2 (down 100.0% YoY), while the FY2025 annual figure was $27.24, down 100.0% from the prior year.
- Total Liabilities advanced to $24526.2 in Q1 2026 per MOLN's latest filing, from $27.24 in the prior quarter.
- Across five years, Total Liabilities topped out at $51.3 billion in Q1 2022 and bottomed at $21.25 in Q2 2025.
- Historically, Total Liabilities has averaged $10.8 billion across 5 years, with a median of $28.1 million in 2022.
- Annual changes were most pronounced in 2023 — Total Liabilities dropped 12.12% — and 2025, when it slumped 100.0%.
- Molecular Partners Ag's Total Liabilities stood at $28.1 million in 2022, then slipped by 12.12% to $24.7 million in 2023, then declined by 21.98% to $19.3 million in 2024, then tumbled by 100.0% to $27.24 in 2025, then jumped by 89935.72% to $24526.2 in 2026.
- Business Quant data shows MOLN's Total Liabilities at $24526.2 in Q1 2026, $27.24 in Q4 2025, and $20778.1 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.57 Bn | 131.72 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.71 Bn | 78.72 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.44 Bn | 60.25 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.06 Bn | 54.93 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.89 Bn | 28.58 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.11 Bn | 9.72 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 24,526.15 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 24,526.15 |
| Dec 31, 2025 | 27.24 |
| Sep 30, 2025 | 20,778.07 |
| Jun 30, 2025 | 21.25 |
| Mar 31, 2025 | 14.35 Bn |
| Dec 31, 2024 | 19.28 Mn |
| Sep 30, 2024 | 17.81 Bn |
| Jun 30, 2024 | 16.64 Mn |
| Mar 31, 2024 | 19.55 Bn |
| Dec 31, 2023 | 24.71 Mn |
| Sep 30, 2023 | 24.80 Bn |
| Jun 30, 2023 | 27.27 Mn |
| Mar 31, 2023 | 24.19 Bn |
| Dec 31, 2022 | 28.12 Mn |
| Sep 30, 2022 | 30.78 Bn |
| Jun 30, 2022 | 34.70 Mn |
| Mar 31, 2022 | 51.27 Bn |
| Dec 31, 2021 | 70.90 Mn |
| Sep 30, 2021 | 56.57 Bn |
| Dec 31, 2020 | 88.85 Mn |